中成药欧盟市场准入十年回顾:产品、政策与挑战
该文回顾2012年以来中成药在欧盟的注册现状,梳理欧盟法规下中成药上市途径,指出仅7个中成药制剂完成注册,其中4个为单组分产品,复方产品注册难度更大,并提出促进注册的建议。
要点
- 中成药可通过完整授权、成熟使用授权或简化注册程序进入欧盟市场。
- 2012年以来仅7个中成药制剂在欧盟注册,4个为单组分产品。
- 复方产品因成分复杂及中欧注册要求差异,注册难度高于单组分产品。
核心结论
- 中成药在欧盟注册数量有限,复方产品注册难度更大,需加强供应链控制和与欧洲机构合作。
研究设计与样本
- 本文为十年回顾性综述,梳理欧盟法规与中成药注册成功案例。
主要发现
- 自2012年首个中成药制剂(颠茄草根单组分)注册以来,仅另有6个中成药制剂成功注册。
- 已注册的7个产品中,4个为单组分产品,其余含多个草药成分的组合。
关键数值与推荐
- 中成药可以药品、膳食补充剂、营养食品或农产品等类别进入欧盟市场,但非药品类别不得宣传药用功效。
临床怎么用
- 中药企业应遵循欧洲主管当局指南,控制供应链和生产过程,并考虑欧洲用药习惯与药品需求。
- 建议与欧洲当地组织建立合作,以促进注册成功。
局限性
- 本文为回顾性综述,未报告系统检索策略或定量数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With increased consumer demand in Europe for natural and efficacious health products, the use of herbal products in the market is rising. Products of Chinese herbal medicine (CHM) could greatly expand European consumer options; however, only seven herbal medicinal products (HMPs) based on CHM formulae have been registered in the European Union (EU) since 2012. PURPOSE: This study reviews the ten-year registration status of HMPs based on CHM formulae in Europe and identifies major challenges and possible solutions for pharmaceutical companies seeking market access for new HMPs. METHODS: An overview of relevant EU regulations identifies pathways to market access in EU countries for CHM products. A discussion of successful attempts to register HMPs based on CHM formulae since 2012 highlights specific challenges that applicants can expect to face. RESULTS: CHM products can enter the EU market as HMPs through the full or well-established use marketing authorization, or through the simplified registration procedure. Alternatively, some CHM products have entered the market as dietary supplements, nutritional foods, and agricultural products; however, under these categories, claims for medicinal use cannot be advertised. Since the registration of the first CHM product, Diao Xin Xue Kang (with the single component of Dioscorea nipponica rhizome), in 2012, only six other HMPs based on CHM formulae have been successfully registered. Among these, four are mono-component products. The remaining two products contain combinations of several herbal ingredients. It is more difficult to register combination products than mono-component products, due to their more complex composition and differences in registration requirements (esp. concerning establishing indications) in China and Europe. CONCLUSIONS: To promote the successful registration of CHM products in Europe, pharmaceutical companies are advised to: demonstrate full control of, and the ability to test, their supply chain and manufacturing procedures following the guidance of European competent authorities; carefully adhere to all steps of the registration process and advices from European competent authorities; take the medication habits and pharmaceutical needs of European market into consideration; and establish collaboration with European local organizations, as appropriate.
引用
- Xiong Y, Li M, Sun P, et al. Market access for Chinese herbal medicinal products in Europe-A ten-year review of relevant products, policies, and challenges. Phytomedicine. 2022. PMID: 35688101. doi:10.1016/j.phymed.2022.154237
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。